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Strengths and limitations of this study
 ► Interviews were performed at the participants’ 
homes, enabling them to speak freely about their 
experiences, wishes and concerns.
 ► A diverse population of older persons was 
interviewed.
 ► Few participants experienced side effects of their 
medication.
 ► Information on decision making at the very start of 
hypertension treatment was limited, due to recall 
bias.
AbStrACt
Objectives Sixty-five per cent of older people have 
hypertension, but little is known about their preferences 
and concerns regarding hypertension management. 
Guidelines on hypertension lack consensus on how to 
treat older people without previous cardiovascular disease 
(CVD). This asks for explicit consideration of patient 
preferences in decision making. Therefore, the aim of 
this study was to explore older peoples’ experiences, 
preferences, concerns and perceived involvement 
regarding hypertension management.
Design Qualitative interview study.
Setting Participants were selected from 11 general 
practitioner (GP) practices in the Netherlands and 
purposively sampled until data saturation was achieved. 
Semistructured interviews were conducted, audio recorded 
and analysed by two researchers using thematic analysis.
Participants Fifteen community dwelling older people 
aged 74–93 years with hypertension and without previous 
CVD participated.
results Interviewees rarely started the conversation 
about hypertension management with their GP, although 
they did have concerns. Reasons for not discussing the 
subject included low priority of hypertension concerns, 
reliance on GPs or trust in GPs to make the right decision 
on their behalf. Also, interviewees anticipated regret 
of reducing medication, fearing vascular incidents. 
Interviewees would like to discuss tailoring treatment 
to their needs, deprescription of medication and ways 
to reduce side effects. They expected GPs to be more 
transparent on treatment effects.
Conclusion Older people describe having little involvement 
in hypertension management, although they have several 
concerns. Since GPs are also known to be hesitant to bring 
up this subject, we signal a conspiracy of silence about 
antihypertensive medication. Through breaking this silence, 
GPs can facilitate shared decision-making on hypertension 
management and better tailored care.
IntrODuCtIOn
General practitioners (GPs) consider hyper-
tension management for older people chal-
lenging.1 For people aged 70 years and over, 
primary prevention guidelines on cardiovas-
cular disease (CVD) lack consensus on (de)
prescribing antihypertensive medication 
(AHM). Treatment decisions are further 
complicated by multimorbidity, shorter life-ex-
pectancy, functional decline and attenuating 
benefit-to-harm ratios.2–5 These uncertainties 
underline the need for patient involvement 
in decision making, to tailor care.5 GPs wish 
to take into account patients’ preferences and 
circumstances. However, in everyday practice, 
these are not always optimally addressed and 
are generally not discussed.1 6 7
Studies on lay perspectives on blood pres-
sure have shown a gap between patients’ 
and doctors’ understanding of hypertension 
and the need for AHM, calling for acknowl-
edgement of these differences and engage-
ment of patients.8 At present, little is known 
about older patients’ involvement in and 
preferences on hypertension management 
in primary care. This is surprising since 65% 
of older people have hypertension and 82% 
of them are using AHM.9 Previous studies 
showed that older people wish to be involved 
in decision-making about their medical 
conditions, and expect their GP to consider 
their personal preferences, situation and 
concerns in decision-making.10 11 However, 
GPs often do not appear to apply shared 
decision-making (SDM) in consultations with 
older patients.12
Insight into older patients’ experiences 
regarding hypertension management can 
support GPs in involving patients in decision 
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Table 1 Interview topic list
Topic Subtopic
Participant characteristics Demographics, including medical history and medication use
Hypertension and 
antihypertensive medication
Frequency of hypertension visits at the GP practice
Topics discussed during hypertension visits at the GP practice: medication use, side effects, 
lifestyle
Experience with hypertension, antihypertensive medication (use) and lifestyle (changes) since 
hypertension was first identified
Attitudes towards hypertension, antihypertensive medication (use), lifestyle and necessity of 
treatment
Experiences with and attitudes towards deprescribing antihypertensive medication
Shared decision-making Received information on hypertension, risk and risk reduction from antihypertensive medication 
and lifestyle during (hypertension) visits at the GP practice
Experience of being involved in decision making and receiving tailored information and care
Views on involvement and tailoring information and care by GP
Experience of trust in the GP and in hypertension management in primary care
Experiences of GPs’ uncertainties in hypertension management in older persons
Experience of and views on necessity, barriers and facilitators to discuss hypertension 
management with the GP
Personal situation and 
preferences
Experience of and views on consideration of personal circumstances and age in decision 
making in hypertension management
Experienced effects of one’s personal situation on views on hypertension and its management
Experienced prioritisation of facets of hypertension and its management
Experienced effect of chronic hypertension and long-term medication use on views on 
hypertension and its management
Future perspectives Wish to change things regarding hypertension management: lifestyle, antihypertensive 
medication use or involvement in decision making with the GP
GP, general practitioner.
making and thus in tailoring hypertension management. 
With this study, we aimed to explore older peoples’ expe-
riences with AHM, how they perceive their involvement 
in hypertension management and what their preferences 
and concerns regarding hypertension management are.
MethODS
Participants
For this qualitative interview study, community dwelling 
hypertensive persons aged 70 years or older were recruited 
from GP practices. We included participants without a 
history of CVD because people who experienced CVD may 
have different motivations for preventing future CVD and 
taking preventative medication, compared with people 
without CVD. To ensure diversity, GPs were asked to purpo-
sively select older persons based on age, gender, educa-
tional level, geographical region, urbanisation, functional 
abilities and experiences with adverse effects of AHM. GPs 
recruited a maximum of two patients per practice. During 
the iterative process of interviewing and analysing, new 
GPs were asked to recruit patients with specific character-
istics that were, so far, underrepresented in our sample. All 
participants who agreed to have their contact details passed 
on to the researchers signed written informed consent and 
participated. A gift voucher (€10) was offered to partici-
pants as compensation for their time.
Data collection
Semistructured interviews with use of a topic list were held 
at the participants’ homes by LR, EB or both between 
January and March 2018. Interviews were conducted in 
Dutch language. In 2018, LR and EB were both female 
GP trainees who had worked a year in a GP practice and 
with experience in qualitative and quantitative research. 
To avoid participants from feeling hesitant to report crit-
icism about GPs, the interviewers introduced themselves 
as researchers and emphasised that results were confiden-
tial and would not be disclosed to the participants’ GP. 
The interview started after introductions, small talk and 
reiterating the research topic and goal. All participants 
were interviewed on their views on hypertension, reasons 
to (not) treat it, the experienced and desired role of the 
GP and their own role in treatment decision making. The 
topic list was modified during the study period, as new 
themes arose during the first interviews. The interview 
topic list is presented in table 1. Once data saturation was 
achieved (after 15 interviews), no new participants were 
Protected by copyright.
 o
n
 N
ovem
ber 4, 2019 at Radboud University Nijmegen.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030742 on 18 August 2019. Downloaded from 
3van Bussel E, et al. BMJ Open 2019;9:e030742. doi:10.1136/bmjopen-2019-030742
Open access
recruited. Field notes were made after each interview. 
The duration of the interviews ranged from 20 to 90 min.
Analysis
All interviews were audio-recorded and transcribed 
verbatim. Qualitative analysis of the data was performed 
following the six phases of thematic analysis according to 
Braun and Clarke:13
1. First, two authors (LR and EB) familiarised themselves 
with the collected data by transcribing the interviews 
verbatim and repeatedly listening to and reading the 
data.
2. LR and EB coded the first six interviews independently 
by systematically going through the data, creating ini-
tial codes. After comparing three independently cod-
ed interviews, codes were merged. The next three in-
terviews were coded independently and compared, re-
sulting in a new set of codes. The other interviews were 
coded by one author using these codes and checked 
by the other. The coding was compared and discussed 
until agreement was found.
3. Identified codes were sorted into potential themes 
which were discussed by the authors (LR, EB, JP, 
EMC, SL) until consensus about potential themes was 
reached.
4. Potential themes were reviewed, and thematic maps 
were made. The collected data were re-read to make 
sure the thematic map was representing the data set. 
Whether data saturation was reached was discussed.
5. The resulting themes were refined and a narrative of 
the found data was considered and discussed by LR, 
EB, JP, EMC, SL.
6. Final analysis was performed, and illustrative examples 
were selected and translated into English, in order to 
answer the research question and compare our analy-
sis to existing literature.
Analysts were GP (trainee) (LR, EB, EMC, SL), neurolo-
gist (ER) and/or anthropologist (LR, JP). For coding and 
analysis MAXQDA Plus 12 (V.12.2.1) was used. Reporting 
of our study is in accordance with the consolidated criteria 
for reporting qualitative research (COREQ).14
Patient and public involvement
There were no patients involved in the development of the 
research question, the design recruitment to or conduct 
of the study. This study was specifically designed to bring 
together the perceptions of hypertensive older patients, to 
inform hypertension management in general practice.
reSultS
In total, 15 individuals aged 74–93 years (mean 81) from 
11 different GP practices were interviewed. Two lived 
in senior apartments, and all interviewees were living 
independently. Three received help with groceries and 
used walking aids. Participants had 3–8 (median 4) 
prescriptions, with 1–3 (median 2) types of AHM and 
level of education ranged from primary school to higher 
education (online supplementary table S1). Partners of 
three interviewees were present in the same room during 
the interview and occasionally confirmed, contradicted 
or supplemented the interviewee. Two interviewees had 
experienced side effects from AHM.
In the conducted interviews, participants expressed their 
concerns and preferences regarding hypertension and 
hypertension management. The results of the interviews 
were structured in four themes: ‘Older peoples’ perspec-
tives on hypertension management are not discussed, 
‘reasons for not discussing needs and preferences regarding 
hypertension management’, ‘concerns and preferences 
regarding hypertension management’ and ‘uncertainty 
about implications of potential choices in hypertension 
management’.
Older peoples’ perspectives on hypertension management are 
not discussed
Interviewees had regular check-ups for their hyper-
tension management, often with a practice nurse. This 
manuscript focuses on the GP, because interviewees 
almost exclusively mentioned the GP as the key profes-
sional engaged in their hypertension care. The GP takes 
decisions on AHM, and participants consider the role 
of the practice nurse solely for check-up, follow-up and 
plain advice. In general, participants did not discuss their 
concerns regarding hypertension management with their 
GPs or felt barriers to do so. When directly asked why, 
interviewees expressed that there was no need to discuss 
the subject or that they experienced barriers to discuss 
issues on hypertension with their GP. During the inter-
views however, all participants reported concerns which 
they did not express to their GP. In general, they expected 
(and waited for) the GP to start the conversation about 
their preferences and concerns regarding hypertension 
management. One participant who felt reluctant taking 
medication reported feeling extremely relieved when her 
GP suggested to reduce her AHM.
‘Then she [the GP] said: “why don’t we try to reduce 
the medication?” At that moment I could hug her, I 
would never dare to ask this myself (…), but if she 
wants to!’ (P6)
There were four key reasons why older persons did not 
start the conversation about hypertension management 
with their GP and four reasons why they desired such a 
discussion.
reasons for not discussing needs and preferences regarding 
hypertension management
Hypertension is not a priority for older people
When participants experience no symptoms of hyperten-
sion or side effects of treatment, they generally did not 
seem to bother much about hypertension or AHM. Inter-
viewees felt hypertension is part of normal ageing, and 
other diseases or circumstances were more important to 
them. Taking AHM daily was part of their routine and did 
not seem to burden these participants.
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‘I am not bothered by it [hypertension], so I never 
think about it. I just never think about it’ (P7)
Reliance on the GP
Fear of jeopardising the relation with the GP, on whose 
care they relied for all other (medical) problems, was a 
barrier to express concerns regarding AHM.
‘You feel dependent on them. You cannot fight with 
them, because what can you do, it is not easy to 
change or find another GP (…) so your dependency 
is bigger than I anticipated.’ (P5)
Also, the perceived authority of the GP formed a barrier to 
discuss any doubts about AHM. Some interviewees felt that 
it would be inappropriate to question the GP’s judgement.
‘I don’t want to do that [discuss reducing medica-
tion], because then I disregard my GP’s advice, my 
GP expects me to follow her advice’ (P1)
The GP knows best
Another reason to remain silent was trust in the GP and 
his or her expertise. Interviewees were convinced that the 
GP would continuously monitor their medication and 
trusted him to start the conversation if this was indicated.
‘I just assume that if he thinks I need another pill, 
that he knows what is best for me’ (P2)
The long-term relation with the GP enforced this trust 
in the GP’s expertise.
‘I thought, well, the doctor is probably right, who am 
I, I didn’t study for it, so he probably knows, because 
he knows me already for a long time’. (P2)
Interviewees found it difficult to truly understand the 
consequences of risk (reduction) for their personal situa-
tion and to interpret that information. This was a barrier to 
making decisions and discussing doubts with their GP. The 
uncertainty made interviewees rely on the advice of their 
GP; the expert.
‘I would like to know [statistics on risk reduction], 
but I would like to get an answer which says some-
thing about my own risk, but there is no such answer, 
that makes it difficult.’ (P5)
Anticipated regret and avoiding responsibilisation
Interviewees were aware of the threats of hypertension. They 
feared CVD, particularly cerebrovascular accidents, since it 
often comes with disability, loss of independence and loss 
of social contacts. One of the strongest motivators not to 
express concerns about drug treatment was anticipated 
regret of developing CVD, when reducing medication.
‘I don’t want to have a stroke (…). I have worked as 
an activity coordinator in nursing homes. I have seen 
the results of strokes, I don’t want to experience that.’ 
(P10)
In addition, actively initiating change in hypertension 
management felt like taking responsibility for the outcome. 
Following doctor’s advice, and ignoring concerns about 
hypertension management was a way to avoid active deci-
sion making and responsibility for one’s own situation.
‘I am not going to be stubborn, because if something 
would happen, it would be my own fault.’ (P2)
In the same line, fear of what might happen kept inter-
viewees from wanting to learn about the details and risks 
of their condition.
‘No, I don’t want that [more explanation of the doc-
tor about AHM], no. I mean, if he explains to me 
what will happen if I don’t take them [medication] I 
would feel uneasy, I think.’ (P7)
Concerns and preferences regarding hypertension 
management
Wish to reduce antihypertensive medication
Even if they did not discuss this with their GP, when asked 
the interviewees showed interest in reducing medication 
and had questions about their use of medication. First, there 
was a wish to minimise overall medication use. Second, 
participants wondered whether (some of) the medication 
could be deprescribed, after a certain period of adequately 
controlled blood pressure. They were curious to find out 
if hypertension would reappear after stopping medication.
‘My blood pressure is always good, my question is, is 
that because of the medication? Or maybe I do not 
need the medication?’ (P14)
Wish to consider one’s age and situation
Taking into account one’s age and situation when deciding 
on continuation of AHM was considered important. For 
instance, a participant expressed the concern that his GP 
would not (sufficiently) adjust his blood pressure levels to 
his older age:
‘Sometimes I feel that they think you are still a young 
guy, because you have to reach certain [blood pres-
sure] levels, which might not be relevant anymore for 
older people.’ (P4)
Some participants thought that relatively high levels of 
stress in the past might have contributed to increased blood 
pressure levels at the start of their treatment and wondered 
whether improvements in their well-being could have had 
beneficial effects, allowing for deprescription of AHM.
‘“Your blood pressure is too high”, well that was based 
on certain levels, it is possible, I don’t have knowl-
edge about that (…), but I keep thinking that it was a 
particular moment’. (P14)
Side effects
Fatigue, fogginess, dizziness, staggering gait, polyuria, 
nausea, burning sensation in the stomach and reduced 
Protected by copyright.
 o
n
 N
ovem
ber 4, 2019 at Radboud University Nijmegen.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030742 on 18 August 2019. Downloaded from 
5van Bussel E, et al. BMJ Open 2019;9:e030742. doi:10.1136/bmjopen-2019-030742
Open access
Figure 1 Final thematic map. Graphical display of the four 
themes of this qualitative interview study, their subthemes 
and mutual relations. AHM, antihypertensive medication; GP, 
general practitioner; HT, hypertension.
exercise tolerance were side effects of AHM that partici-
pants reported. These side effects reduced quality of life 
and resulted in the wish to re-evaluate the benefits and 
harms of continuing or stopping AHM. For some, this was 
a reason to discuss hypertension treatment with their GP.
‘If it stays like it is at the moment, I think I will accept 
it. But that burn in your stomach and the feeling that 
you have to throw up, I don’t like that, that was not 
acceptable for me. It needs to be in my opinion with-
in reason, these side effects. If it becomes too much, 
I won’t accept it. I would then say: “I don’t want that 
drug anymore”.’ (P15)
Lack of transparency in GPs’ considerations
The interviewees who experienced side effects of AHM 
learnt about the uncertainty of their GP regarding hyper-
tension management, during their struggle to find a 
balance between prevention of CVD and side effects. 
Despite the knowledge that GPs do not know the optimal 
blood pressure targets in older age and thus the right 
treatment, one of them felt reluctant to discuss his own 
doubts with the GP. Still, he would have appreciated it 
if his GP had shown and shared more of his uncertainty, 
to make room for alternative outcomes (instead of blood 
pressure target as the only goal).
‘They really don’t know. They have statistics, but 
whether you meet those or not, they don’t know, they 
just don’t know. I think they should be more transpar-
ent about that.’ (P5)
uncertainty about implications of potential choices
Overarching the aforementioned themes is the uncer-
tainty of implications of choices regarding hyperten-
sion management. Interviewees were ambivalent about 
deciding which of their concerns and preferences were 
most important and should be acted on.
‘It [taking antihypertensive medication] is a compro-
mise. (…) Of course, if it would be better [to take 
more medication] and if it lowers my risk I would 
accept it. I wouldn’t be happy about it. I would be 
reluctant [to take medication] but it would be neces-
sary, it would be better because you would lower your 
risks.’ (P3)
The final thematic map is shown in figure 1.
DISCuSSIOn
Older people do not feel sufficiently involved in deci-
sion making about hypertension management in general 
practice, while they do have many unexpressed concerns. 
Reasons not to raise these concerns are the low priority 
compared with other complaints or diseases, being reliant 
on their GP, trust in their GP to make the right decision 
on their behalf and anticipated regret of incident CVD 
in absence of treatment. Participants could benefit from 
overcoming these barriers but wait for their GP to bring 
up the subject. They often have the wish to reduce medica-
tion, to tailor management to their individual situation, to 
avoid side effects and to receive transparent information on 
expected treatment effects. Last, participants experienced 
ambivalence regarding their concerns and preferences in 
hypertension management, hampering their perceived 
capacity for decision making on their own situation.
Strengths of this study include that interviews were 
performed at the participants’ homes, by researchers who 
were independent of their GPs. This way, we enhanced 
trust and enabled a diverse population of older persons 
to speak freely about their experiences, wishes and 
concerns. Because of the background of the authors 
(GPs and anthropologists), the analyses had a prag-
matic but open character, looking for themes that may 
inform and improve primary care. The population was 
diverse in terms of age, sex, comorbidities, educational 
level and geographical region. In terms of dependency 
and medication use, the population was less diverse, with 
all participants being independent to some extent and 
taking multiple medications. With only two participants 
(recently) experiencing side effects of AHM, this groups 
representation was small in our study, which may have 
limited our findings. It was difficult to include persons 
with side effects from AHM, since most older persons 
were using AHM for a long time without any problems, 
with difficulty to recall past episodes of problems or reluc-
tance to discuss this with their GP. It is reported that in 
adults up to 70 years of age, 85% of those starting AHM 
experienced side effects,15 while of long-term AHM users 
(up to 84 years), 20% reported side effects.16
Although we aimed to include people without a history 
of CVD, two participants probably had had CVD (P9 and 
P15) judging from the interviews and their medication 
list (acenocoumarol, acetylsalicylic acid). When selecting 
participants, we relied on the GP to have assessed the 
inclusion criteria. However, in our study opinions did not 
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differ from participants with definite absence of CVD in 
their medical history, particularly not on motivation for 
preventing future CVD or willingness to use preventative 
medication. Decision making at the very start of hyper-
tension treatment was hard to recall, limiting the infor-
mation on treatment initiation. Yet, a large proportion of 
Dutch older adults have long-term hypertension and our 
results apply to this group.9
Our results provide insight into experiences and views 
of older persons with hypertension, that may apply to 
other developed countries. Although the next generation 
of older people may have more difficulty with accepting 
authority in GPs and less problems with speaking up about 
their concerns, the complexity of decisions in hyperten-
sion management is not likely to change.
A conspiracy of silence
There appears to be a conspiracy of silence, in which 
both the older patient and the GP do not express their 
concerns regarding antihypertensive treatment. From 
previous studies, it is known that GPs feel that they hardly 
involve older persons in decisions on hypertension 
management.1 6 7 Reasons are time constraints, automated 
prescriptions, negative emotional impact on patients and 
anticipated regret in case of cardiovascular events.6 This 
study showed that older people too have the impression of 
no or minimal involvement in their hypertension manage-
ment in primary care. From prior studies, little is known 
about (the perceived) involvement of older people in their 
hypertension management.17 This contrasts the wish for 
greater patient involvement in hypertension management 
among both GPs and older patients.1 6 7
reasons to remain silent
There is uncertainty and ambivalence in prioritising pref-
erences and concerns regarding AHM use among older 
people in our study. Ambivalence has previously been 
shown in qualitative studies among older people. AHM 
can provide a feeling of security regarding prevention of 
CVD, but older patients also worry about side effects and 
long-term adverse effects of taking chronic medication,18–20 
are cautious to take preventative medication and prefer 
minimising medication-use.19 21 Concerns are generally 
outweighed by the perceived necessity of treatment and 
their GP’s recommendation.21 22 In our study, side effects 
were the only reason to discuss alternatives with the GP.
Reliance on the GP was a major barrier that is also 
recognised in SDM in other fields. Patients are in a vulner-
able position and can feel too dependent to bring up 
concerns in interaction with the doctor.23 Other barriers 
to active involvement in decisions were reluctance to bear 
responsibility for cardiovascular outcomes and antici-
pated regret, also known from SDM in other fields.23 It 
was previously shown that anticipated regret has stronger 
associations with health behaviour than other anticipated 
negative emotions and risk appraisals.24
In our study, hypertension and hypertension manage-
ment were generally given low priority. When taking 
AHM, participants felt safe in terms of preventing CVD 
morbidity and mortality. However, older people overes-
timate both the risks of hypertension and the benefits 
of medication. For example, hypertensive people with a 
mean age of 73 years estimated their stroke risk to be 40% 
within 5 years and expected over 50% stroke risk reduc-
tion from AHM, while in fact 5-year risk of cardiovascular 
events for this group is 5%–20% and stroke risk reduction 
from AHM is 24%–42%.25–27 After being shown the actual 
risks and benefits, a quarter of 75 older patients with 
hypertension participating in a qualitative study became 
uncertain about AHM use or would decline to take it.25 
Trust in GPs and AHM seems high and also unrealistic, 
so participants’ choices are often based on false or at least 
incomplete information. Concerns about taking medica-
tion, side effects and tailoring to the individual situation 
could receive different prioritisation if patients would be 
better informed and if GPs would be more transparent on 
their uncertainty.
breaking the silence
It is important to break the silence since older patients 
generally wish to be involved in decision-making about 
their medical issues, despite the abovementioned reasons 
to remain silent.10 GPs also value patient involvement in 
decision making, especially since guidelines leave room 
for discussion.6 28 By breaking the silence, GPs could 
guide older patients in their ambivalent feelings about 
AHM and improve personalised care. For example, once 
started, lifelong use of AHM is the current standard of 
care. However, a systematic review showed that after 2 
years of withdrawal of AHM, hypertension did not return 
in 26% of patients (mean age 41–76 years). This justifies 
an AHM withdrawal attempt in well controlled patients, 
if they wish to do so.29 In addition, more transparency 
could reduce misinterpretations and lower the threshold 
to start discussing factors important to patients in hyper-
tension management.
Heterogeneity exists in how older people want to be 
involved in decision-making. Older patients with multi-
morbidity and healthcare professionals agreed that SDM 
in older patients requires a continuous dialogue between 
professional and patient.30 Contextual factors for 
receiving information, such as having enough time and 
having a good relationship with professionals involved, 
are considered of great importance.31 Elements in deci-
sion making unique to older people are the opportunity 
for input from trusted others and discussion of decisions’ 
impacts on patients daily lives.32
Older persons generally do not start the dialogue them-
selves; they wait for their GP to do so. In our study and 
also in SDM in other fields of medicine, older patients 
experience barriers to participate in decision making 
about their care.33 Since most barriers are related to the 
GP, including the authority ascribed to them as well as 
time constraints, we recommend that GPs take the initia-
tive to break the silence.22
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Implication for practice
To break the conspiracy of silence, GPs should explicitly 
and repeatedly discuss hypertension treatment with their 
patients on chronic AHM. This is the only way to come to 
true SDM about hypertension treatment and may lead to 
adaptation and potentially cessation of AHM in those for 
whom the benefits not clearly outweigh the burden.
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